June 12, 2007 — Response Biomedical Corporation today announced that it has been granted a medical device license by Health Canada to market its RAMP NT-proBNP Test.
The company currently markets the product in Europe and has applied for FDA clearance of the test in the United States.
Measurement of NT-proBNP aids in the diagnosis and assessment of severity in individuals suspected of having congestive heart failure (CHF) and may aid in the risk stratification of patients with acute coronary syndrome and heart failure. This allows the company to market, in Canada, diagnostic tests for a full line of cardiac markers for acute myocardial infarction (AMI) and congestive heart failure (CHF).
"We are very pleased to receive country of origin approval to market the NT-proBNP test in Canada," said Bill Radvak, President and CEO. "We have been able to offer a comprehensive line of AMI diagnostics, including Troponin I, CK-MB and Myoglobin, and the addition of NT-proBNP for CHF should heighten interest in our cardiovascular product line."
For more information: www.responsebio.com